This table provides a snapshot of our performance over the last three years. More detailed information and statistics for each area can be found in the appropriate sections of this website.
Economic ($m) *
| | 2008 | 2007 | 2006 |
|---|
| Sales | 31,601 | 29,559 | 26,475 |
Operating costs
(Sales minus operating profit) | 22,457 | 21,465 | 18,259 |
| Total wages | 6,916 | 7,108 | 6,355 |
| Retained earnings | 11,572 | 10,624 | 11,348 |
Interest
(Interest on debt and commercial papers + interest on overdrafts and other financial costs + interest on post-employment defined benefit plan liabilities) | 1,303 | 1,061 | 547 |
| Dividends | 2,739 | 2,641 | 2,220 |
| Re-purchases of shares | 610 | 4,170 | 4,147 |
| Taxation | 2,209 | 2,563 | 2,169 |
Environmental - Greenhouse gases 1
| | 2008 | 2007 | 2006 |
|---|
| CO2-equivalents (million tonnes) | 1.22 | 1.29 | 1.31 |
| Index (tonnes/$m sales) | 39 | 44 | 50 |
Environmental - Energy
| | 2008 | 2007 | 2006 |
|---|
| GWh | 2,300 | 2,390 | 2,450 |
| Index (MWh/$m sales) | 73 | 81 | 93 |
Environmental - CFCs - Total Ozone Depletion Potential
| | 2008 | 2007 | 2006 |
|---|
| CFC11-equivalent (tonnes) | 22 | 36 | 40 |
| Index (kg/$m sales) | 0.7 | 1.2 | 1.5 |
Environmental - Water Use
| | 2008 | 2007 | 2006 |
|---|
| Usage (million cubic metres) | 4.3 | 4.8 | 5.1 |
| Index (cubic metres/$m sales) | 130 | 160 | 190 |
Environmental - Waste
| | 2008 | 2007 | 2006 |
|---|
| Hazardous waste (kte) | 28.9 | 27.9 | 29.4 |
| Total waste (kte) | 54.1 | 57.6 | 60.3 |
| Index – total waste (tonnes/$m sales) | 1.71 | 1.95 | 2.28 |
Social - Safety and Health: AstraZeneca employees
| | 2008 | 2007 | 2006 |
|---|
| Accidents with injury2 with and without days lost (per million hours) | 2.28 | 2.65 | 2.37 |
| Accidents with injury2 with days lost only (per million hours) | 2.12 | 2.21 | 1.92 |
| Cases of occupational illnesses (per million hours) | 1.04 | 0.99 | 0.97 |
Social - Safety and Health: AstraZeneca employees and contractors
| | 2008 | 2007 | 2006 |
|---|
| Accidents with injury2 with and without days lost (per million hours) | 2.38 | 2.73 | 2.43 |
Social - Number of animals used in research
| | 2008 * | 2007 | 2006 |
|---|
| Number of animals used in research | 376,000 | 284,500 | 288,000 |
Social - Sales and Marketing: Number of confirmed breaches
| | 2008 * | 2007 | 2006 |
|---|
| Number of confirmed breaches of external codes or regulations | 15 | 32 | 44 |
Social - Site audits
| | 2008 | 2007 | 2006 |
|---|
| Site SHE and Security audits | 19 | 26 | 18 |
Social - Community Support ($m) *
| | 2008 | 2007 | 2006 |
|---|
| Community sponsorships | 57.5 | 51.7 | 37.0 |
| Charitable contributions | 14.5 | 18.3 | 19.0 |
| Total | 72.0 | 70.0 | 56.0 |
| Product donations and patient assistance programmes valued at average wholesale price ($m) | 646 | 518 | 443 |
Regulatory infringements - safety, health and environment
| | 2008 | 2007 | 2006 |
|---|
| Prosecutions | 0 | 0 | 0 |
| Regulatory enforcement actions | 5 | 1 | 2 |
| Regulatory warnings and alerts | 2 | 2 | 4 |
* including MedImmune
1. Figures are calculated in line with the Greenhouse Gas (GhG) Protocol guidance (ghgprotocol.org). Source for calculation of CFC figures is AstraZeneca sales data.
2. Serious and fatal as described by the reporting procedure.
n/a = not applicable
The content of this page was externally assured by Bureau Veritas, February 2009.
26.95 GBP